Cardiovascular autonomic function was assessed in 9 subjects with Raynaud's phenomenon. The underlying diseases were systemic lupus erythematosus (n = 5), systemic sclerosis (n = 3) and rheumatoid arthritis (n = 1). Five standard non-invasive tests, 3 of heart rate and 2 of blood pressure, were employed. Compared with age and sex matched controls (n = 25), the number of values abnormal was 24 of 45 (53%) overall and between one and 4 (median, 2) individually. Significant differences were present for 3 tests, two of heart rate and one of blood pressure.
Introduction
While developing a reference range for cardiovascular autonomic function tests,"2 we observed that 3 individuals with Raynaud's disease (RD)3 had an exceptionally small rise in blood pressure (BP) in response to isometric exercise (Gledhill, R.F., Retief, J., unpublished data). This occasioned a study of subjects with Raynaud's phenomenon (RP).3 Five standard tests were employed and one or more values was abnormal in each of the 9 cases.
Despite an ever-increasing number of therapeutic agents available, many patients with RP continue to suffer disabling symptoms. Against that background, these same subjects subsequently were given triiodothyronine (T3) as remedial therapy for vasospastic attacks -a form of treatment recommended in standard texts,3 but apparently overlooked since Peacock4 published an encouraging report of its use 25 years previously.
On account of the sustained remission that followed5 (an observation later affirmed in a formal trial of experimental design6) and having regard to the speculative role of the sympathetic system in the pathogenesis of such symptoms,7 autonomic tests were repeated. A significant trend towards normal values was found. Corrective effects on autonomic dysfunction to T3 constitutes, we believe, a quite novel observation.
Methods

Study population
The 9 subjects comprised the total RP population then attending our Rheumatic Diseases clinic. Each gave a history of episodic cold-induced biphasic or triphasic colour changes of the digits associated with pain or numbness.3 All were females, their ages ranging from 27 Post-treatment assessments of RP subjects were performed between weeks 4 and 9 (first reassessment) and between weeks 12 and 18 (second reassessment) after introduction of T3. One subject defaulted after the first reassessment.
Nerve conduction studies
Recordings were performed on all 9 RP subjects. The median (motor and sensory), peroneal (motor) and sural nerves, on one or other side, were sampled in every case using standard techniques. Sampling took place shortly after T3 had been introduced. Reference data were obtained from 44 healthy volunteers matched for age and sex and studied concurrently (controls). Seventeen of these persons were among the 25 who volunteered as controls for autonomic function tests. Individual RP subjects Test values were deemed abnormal if they fell below the lowest equivalent for controls. The number oftests abnormal individually was 1 (n = 1), 2 (n = 4), 3 (n = 2) or 4 (n = 2) pretreatment; nil (n = 1), 1 (n = 5), 2 (n = 2) or 3 (n = 1) at the first reassessment; and nil (n = 4) or 1 (n = 4) at the second reassessment. This tendency of values to normalize following treatment was present, to a varied degree, in every case. .5) 11 (2.3) 27 (3.9) Values for the 9 controls tested twice did not differ significantly (P> 0.05) between the two assessments for any of the 5 tests.
T3 administration
Resting PR and BP did not change significantly (P>0.05) when comparing pretreatment values with those at the first and the seicond reassessments.
Nerve conduction studies All 9 RP subjects had evidence of somatic neuropathy at one (n = 7) or more (n = 2) of the sites sampled. The sural nerve was involved in 8 instances and the median sensory nerve, the median motor nerve and the peroneal nerve in one instance each. Abnormalities comprised nerve inexcitability (sural nerve only, n = 2), reduced amplitude of evoked action potential (n = 3) or mild ( < 20%) slowing of conduction velocity (n = 6). Such findings are typically seen with axonal nerve degeneration.
Discussion
Autonomic dysfunction has been described in each of the underlying diseases that affected the RP subjects we studied.'3'9 This, together with a frequency greater than suspected when sought systematically,'4-'9 may be sufficient explanation for its presence in every case. At the same time, we (Gledhill, R.F. and Retief, J., unpublished) and others'7 have found cardiovascular autonomic tests to be abnormal in otherwise healthy persons with RD. Additional studies are required in both RP and RD before the question of pathogenesis in the present cases can be considered clearcut.
Test values taken as a whole showed a significant trend towards normality following therapy with T3. This general tendency was present in each of the 5 tests, attaining levels of significance for 2 of the 3 that previously differed. In the one other, moreover, all individual values now fell within the range of controls (data not shown). Improvement in autonomic function occurred to a greater or less degree in all 9 subjects. To the extent that readings did not differ in a similar number of controls on retesting, we believe the differences between pretreatment and post-treatment values were not due to spontaneous variation and that, in the absence of confounding variables, T3 was the factor responsible. The trial was non-experimental in design, however, and such inferences must necessarily remain tentative. We should nevertheless emphasize that values for change in HR and BP on standing, which are not effort dependent, improved to an equal extent, arguing against a placebo response. Also, the fact that the outcome of the study -with respect to autonomic function -was unanticipated would have largely neutralized any effects of observer bias.
Each of the RP subjects had a collagen vascular disease together with evidence of somatic peripheral neuropathy. Such neuropathies are thought to have a vascular pathogenesis20 and this must be reckoned with when considering mechanisms underlying the corrective effects of T3. Indeed, the dosages of T3 we used might be expected to increase tissue blood flow2' with consequent benefit to neural function. 22 It was unfortunate that nerve conduction studies could not be repeated to assess whether such an eventuality did in fact materialize.
Augmentation of cardiovascular reflexes may have occurred by other, more direct means. Thus, T3 fulfills many criteria of an adrenergic neurotransmitter precursor.23 It also increases the function of central presynaptic alpha-2 adrenoreceptors,24 stimulation of which enhances the sensitivity of the baroreceptor reflex.25 Furthermore, thyroid hormones not only intensify the metabolic activity of both cardiac and smooth muscle26 but also have the attributes of a neuromodulator.27'28 Finally, experimental hyperthyroidism leads to profound changes in the metabolism of several biogenic amines with putative central 29 neurotransmitter properties.
Whatever the mechanism(s), our findings suggest a formal, experimental trial ofT3 in autonomic insufficiency is merited. 
